

ASX Release

TALi FEATURED IN GLOBAL DIGITAL THERAPEUTICS ALLIANCE SHOWCASE**HIGHLIGHTS**

- **TALi showcased by Digital Therapeutics Alliance in organisation product library**
- **One of only a handful of digital therapeutics technologies showcased with evidence based and in-market solutions recognised by global regulators**
- **TALi now a member of the Digital Therapeutics Alliance to further enhance the position of the Company in the global digital therapeutics segment**

TALi Digital Ltd (ASX: TD1, “**TALi**” or “**the Company**”), a leading global digital health business is pleased to update the market on the showcase of TALi in the Digital Therapeutics Alliance (DTA) product library. Access to the showcase can be found here: <https://dtxalliance.org/understanding-dtx/product-library/>

These types of initiatives are undertaken by the DTA “To help key stakeholders understand and differentiate digital therapeutics from the thousands of other mobile health apps that are available, DTA developed this library to highlight evidence-based innovative digital therapeutics (DTx) products. The products in this library are currently in-market and meet the definition of a DTx product and attest to aligning with industry Core Principles”.

TALi has also been accepted as a member of the DTA. Managing Director and CEO of TALi, Mr. Glenn Smith remarked, “TALi is pleased to join this preeminent global organisation where members are regarded as industry thought leaders in healthcare worldwide. The showcase of TALi combined with our membership of the DTA will only serve to assist our goal of executing additional partnerships in various jurisdictions to ensure the commercialisation success for TALi”.

Members of the DTA may be found here: <https://dtxalliance.org/join-dta/>

Founded in 2017, the Digital Therapeutics Alliance is a 501(c)(6) non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of DTx. As the leading international organization on digital therapeutic thought leadership and education, the Digital Therapeutics Alliance provides patients, clinicians, payors, and policymakers with the necessary tools to evaluate and utilize DTx products.

Release authorised by:

The Board of TALi Digital Limited

CONTACT

Corporate

Glenn Smith
TALi Digital Managing Director
1300 082 013
investors@talidigital.com

Investors

Bellevue Investor Relations
Katie Mackenzie
0455 502 197
kmackenzie@bellevueir.com.au

Catherine Ross
0421 997 481
catherine@irconsult.com.au

About TALi Digital

TALi [TALi Digital Limited (ASX: TD1)] is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence and game-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy and places TALi at the forefront of patient experience and early intervention for attention related conditions. We believe in healthy, happier minds – they start here with TALi.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) along with a core research program exploring applications for at populations afflicted with Mild Cognitive Decline (MCI has been found to often been a precursor to recognizing Alzheimer’s disease and other forms of dementia).

At TALi, our vision is to deliver a personalised digital experience to enhance cognitive care. Learn more at talidigital.com.